Evofem’s Phexxi birth control method prevented 99% of pregnancies, post analysis shows
Evofem Biosciences (NASDAQ:EVFM) on Thursday said a post analysis of its phase 3 trial evaluating Phexxi showed that the birth control method prevented 99% of pregnancies.
The analysis was based on 101 pregnancies in about 1.2K women who used Phexxi over 24.2K acts of intercourse.
Phexxi was approved by the U.S. FDA in May 2020 based on the results of the late-stage trial, called AMPOWER, which enrolled about 1.3K women in the U.S., as well as combined safety data from AMPOWER and a previous late-stage trial called AMP-001.
EVFM’s Phexxi works by modulating vaginal pH levels which in turn immobilizes the sperm. Phexxi is not effective when used after intercourse.
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
